Article
Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention.
Thrombosis research - 1 Dec 2011
Ono Takamichi, Kaikita Koichi, Hokimoto Seiji, Iwashita Satomi, Yamamoto Koichiro, Miyazaki Yuji, Horio Eiji, Sato Koji, Tsujita Kenichi, Abe Tomohide, Deguchi Mariko, Tayama Shinji, Sumida Hitoshi, Sugiyama Seigo, Yamabe Hiroshige, Nakamura Sunao, Nakagawa Kazuko, Ogawa Hisao
Abstract excerpt
INTRODUCTION: Carriers of reduced-function CYP2C19 allele on antiplatelet therapy show diminished platelet inhibition and higher rate of clinical risk. The purpose of this study was to determine cut-off levels of VerifyNow P2Y12 system associated with effective inhibition of on-clopidogrel platelet aggregation to predict carriers of CYP2C19 reduced-function allele among patients undergoing percutaneous coronary...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.